UPDATE: Thailand "will not end" compulsory licenses
Thailand's Commerce Ministry has requested a ruling from the country's Council of State on the legitimacy of the compulsory license issued against France-based drug major Sanofi-Aventis' breast cancer agent Taxotere (docetaxel). The Public Health Minister, Chavarat Charnviakul, had previously stated his intention to resist attempts by Sanofi to have the previous, military-backed government's populist policy of compulsory licensing of cardiovascular and oncology products (Marketletters passim). The Bangkok Post reported that the French firm had offered to compensate Thailand's Government Pharmaceutical Organization for the added cost of the branded products compared with copy drugs made in India.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze